Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
about
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy.Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide.Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer TherapyDiscovery of a Novel Microtubule Targeting Agent as an Adjuvant for Cancer Immunotherapy
P2860
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Combination immunotherapy with ...... ppresses head and neck cancer.
@en
type
label
Combination immunotherapy with ...... ppresses head and neck cancer.
@en
prefLabel
Combination immunotherapy with ...... ppresses head and neck cancer.
@en
P2093
P2860
P1433
P1476
Combination immunotherapy with ...... uppresses head and neck cancer
@en
P2093
Alast Ahmadi
Cristiana Guiducci
Dennis A Carson
Ezra Ew Cohen
Fumi Sato-Kaneko
Judith A Varner
Karen S Messer
Kazutaka Kitaura
Megan M Kaneda
P2860
P356
10.1172/JCI.INSIGHT.93397
P577
2017-09-21T00:00:00Z